alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 626–650 of 1,212 studies published 2019 (page 26 of 49) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

APOE genotype and sex affect microglial interactions with plaques in Alzheimer's disease mice

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Acta neuropathologica communications 2019-05-21

Microglia affect Alzheimer's disease (AD) pathogenesis in opposing manners, by protecting against amyloid accumulation in early phases of the disease and promoting neuropathology in advanced stages. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

✓ Peer-reviewed alzhub usefulness score 47 out of 100. PloS one 2019-08-20

Alzheimer's disease (AD) remains a clinical diagnosis but biomarkers from cerebrospinal fluid (CSF) and more lately amyloid imaging with positron emission tomography (PET), are important to support a diagnosis of AD. 4 key findings →

Participants: 64 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-modal latent space inducing ensemble SVM classifier for early dementia diagnosis with neuroimaging data

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Medical image analysis 2019-12-28

Fusing multi-modality data is crucial for accurate identification of brain disorder as different modalities can provide complementary perspectives of complex neurodegenerative disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neuroscience 2019-09-04

Alzheimer's disease (AD), a primary cause of dementia in the aging population, is characterized by extracellular amyloid-beta peptides aggregation, intracellular deposits of hyperphosphorylated tau, neurodegeneration and glial activation in the brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mediterranean diet adherence and cognitive function in older UK adults: the European Prospective Investigation into Cancer and Nutrition-Norfolk (EPIC-Norfolk) Study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The American journal of clinical nutrition 2019-10-01

Higher adherence to the MedDiet is associated with better cognitive function and lower risk of poor cognition in older UK adults. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Families' Experiences With End-of-Life Care in Nursing Homes and Associations With Dying Peacefully With Dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Medical Directors Association 2019-02-01

Families' reports of unpleasant experiences with end-of-life care may inform practice to improve perceived quality of dying of their loved ones. 4 key findings →

Participants: 252 Evidence: low

Full summary, score breakdown and related studies → Original source

Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Nature medicine 2019-01-14

Vascular contributions to cognitive impairment are increasingly recognized 1-5 as shown by neuropathological 6,7 , neuroimaging 4,8-11 , and cerebrospinal fluid biomarker 4,12 studies. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Functional ability is associated with higher adherence to behavioral interventions in mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Clinical neuropsychologist 2019-10-13

Two-hundred and thirty-seven participants completed the 6-month post-intervention follow-up measures, 228 participants completed the 12-month measures, and 218 participants completed the 18-month measures. 5 key findings →

Participants: 272 Evidence: low

Full summary, score breakdown and related studies → Original source

Salivary Biomarkers for Alzheimer's Disease and Related Disorders

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurology and therapy 2019-12-12

The search for accessible and cost-effective biomarkers to complement current cerebrospinal fluid (CSF) and imaging biomarkers in the accurate detection of Alzheimer disease (AD) and other common neurodegenerative disorders remains a challenging task. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia (New York, N. Y.) 2019-08-16

The budgetary impacts are not insignificant but are small in comparison to the likely market price of any disease-modifying treatments or to the probable costs of missed or inaccurate diagnosis. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early-onset Alzheimer Disease and Its Variants

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Continuum (Minneapolis, Minn.) 2019-02-01

Neuroimaging features of early-onset AD in comparison to late-onset AD include greater frequency of hippocampal sparing and posterior neocortical atrophy, increased tau burden, and greater connectomic changes affecting frontoparietal networks rather than the default mode network. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Late-onset Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Continuum (Minneapolis, Minn.) 2019-02-01

Vascular risk factors, sleep disorders, and traumatic brain injury are associated with an increased risk of AD, while increased cognitive and physical activity throughout the lifespan reduce the risk of disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Efficacy of Group Reminiscence Therapy on Cognition, Depression, Neuropsychiatric Symptoms, and Activities of Daily Living for Patients With Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of geriatric psychiatry and neurology 2019-10-23

The current study aimed to investigate the effects of group reminiscence therapy on cognitive function, depression, neuropsychiatric symptoms, and activities of daily living in patients with mild-to-moderate Alzheimer disease (AD). 1 key finding →

Participants: 45 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Dynamic 11C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019-03-08

ANOVA revealed significant group differences in lateral ventricular SUVR across the Alzheimer, mild cognitive impairment, and healthy control groups ( P = 0.004). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Companion robots for older people: importance of user-centred design demonstrated through observations and focus groups comparing preferences of older people and roboticists in South West England

✓ Peer-reviewed alzhub usefulness score 46 out of 100. BMJ open 2019-09-26

The observed misalignment of opinion between end users and developers on desirable design features of companion robots demonstrates the need for user-centred design during development. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed